Stoke Therapeutics Inc Stock
Price
Target price
-
-
-
-
-
€21.78
WKN: A2PLTL / Symbol: STOK / Name: Stoke Therapeutics / Stock / Biotechnology & Medical Research / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Stoke Therapeutics Inc Stock
We see a rather positive sentiment for Stoke Therapeutics Inc with 13 Buy predictions and 2 Sell predictions.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Stoke Therapeutics Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Stoke Therapeutics Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Stoke Therapeutics Inc vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Stoke Therapeutics Inc | - | 78.846% | 53.719% | 32.857% | 93.750% | -69.000% | - |
Personalis Inc | -0.750% | -2.467% | -3.170% | -44.600% | -35.385% | -92.851% | - |
Immuron | 5.360% | -0.885% | 44.516% | 30.994% | 34.132% | -55.200% | - |
Comments
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its price target raised by analysts at Wedbush from $13.00 to $17.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) was upgraded by analysts at TD Cowen from a "market perform" rating to an "outperform" rating.
Show more
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Show more
Ratings data for STOK provided by MarketBeat